Gelatin Capsule Shell Cross-Linking - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gelatin Capsule Shell Cross-Linking
The authors develop a pratical approach to avoid unwanted interactions between pepsin and SLS in dissolution Tier II tests.


Pharmaceutical Technology
Volume 35, Issue 5, pp. 62-68

Hard gelatin capsules are a common solid oral dosage form, but exposure to accelerated conditions, e.g. 40 °C and 75% relative humidity (RH), can cause capsule shell cross-linking. Capsule shell cross-linking arises from gelatin polymerization, a process facilitated by high temperature, high humidity, ultraviolet (UV) and visible irradiation, dyes, and aldehydes (1–4). The main impact of gelatin cross-linking is prolonged capsule disintegration time, and a subsequent slow-down of drug product dissolution rate. In the event that hindered dissolution arises from gelatin cross-linking and the product fails specification, USP <711> recommends the addition of enzymes (e.g., pepsin) to the dissolution medium to serve as the Tier II dissolution test (5). It is important, though, to confirm that dissolution failure is a direct outcome of cross-linked gelatin shells rather than degradation of drug product performance.

Sodium lauryl sulfate (SLS) is a surfactant commonly used in dissolution medium to improve the solubility of poorly water-soluble drugs. The presence of SLS in dissolution medium deactivates pepsin, which complicates the Tier II method described above (6). One option would be to redevelop the dissolution method and abandon SLS. But this option could be costly in time and resources, and may discourage the use of SLS in capsule formulations in general, despite its excellent solubilizing capability, low cost and ease of use. Performing Tier II dissolution tests in the presence of SLS is considered beneficial to the development and quality control of capsule formulations.

This article will detail the experimental procedures and the study results of a case where the above issues were encountered and tackled in the development of a capsule formulation. A slowdown in dissolution rate was discovered for the gelatin capsule formulation when it was stored at accelerated conditions of 40 °C and 75% RH for three months.

Materials

Size one opaque hard gelatin capsule shells were purchased from Capsugel. Dissolution was performed using USP Apparatus II (paddles), Model VK 7000 (Varian). Stand-alone UV–Vis spectrometer with diode array capacity, Model 8453, was from Agilent. Capsule sinkers (size 8/23) were from Sotax. SLS (reagent grade > 99%) was purchased from Fisher Scientific. Full flow cannula filters (10 µm) were from Quality Lab Accessories. Pepsin (800–2,500 units/mg) purified from porcine gastric mucosa was purchased from Sigma-Aldrich. All other chemicals were ACS grade or equivalent.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here